

Milford KiwiSaver Plan

KiwiSaver Aggressive Fund

Monthly Fact Sheet as at 31 October 2022



Portfolio Managers



Stephen Johnston
Portfolio Manager



Jonathan Windust
Co-Portfolio Manager

The Fund gained 4.3% in October. Despite the uncertain backdrop, share markets globally rebounded strongly in October.

In our international portfolio, our healthcare holdings continue to be a bright spot, posting strong returns in October. Healthcare is one of our favoured sectors, offering attractive valuations and compelling long-term growth opportunities, benefitting from the rapidly ageing global population.

The top contributor in October was US health insurer Elevance (+20.4%). Business fundamentals remain strong at Elevance with strong growth in members. Given its defensive business model, its earnings can still grow even in a recessionary environment. US private hospital HCA (+18.3%) also outperformed in October, after reporting solid third quarter earnings. We remain constructive on HCA, given its dominant market position in key states and a strong management team. Medical devices company Boston Scientific (+11.3%) posted strong gains, benefitting from strong procedure volume growth, as we come out of the pandemic. We added to our position in October.

Underperformers in October were predominately large cap technology stocks, as third quarter earnings disappointed. Both Amazon (-9.3%) and Meta (-31.3%) were a drag on performance in October. We are currently reviewing both positions to ensure our long-term investment thesis is still intact.


Closer to home, Australasian markets bounced back in October. Australian miner IGO (+11.6%), continued its terrific run. IGO is a key beneficiary of one of the strongest trends globally, the transition to electric vehicles. In the NZ market, Mainfreight (+12.8%) bounced back from a weak September, after providing a solid first half trading update, with management upbeat about the outlook.

Looking ahead, the economic outlook remains uncertain, and we will retain higher levels of cash, until we see a sustained decline in inflation.

To view Milford's November 2022 Market and Economic Review please see milfordasset.com/fact-sheet.

Cumulative Fund Performance

(after fees and before tax)



Assumes the growth of \$10,000 invested at the Fund's inception date.

Key Fund Facts

Objective ²	To maximise capital growth over the minimum recommended investment timeframe
Description	Primarily invests in international equities, with a moderate allocation to Australasian equities
Minimum recommended investment timeframe	10 years +
Target Allocation	5% Income Assets / 95% Growth Assets
Neutral FX Exposure	24.5%
Net Asset Value (NAV)	\$818.9 M
Buy-sell Spread	None - swing pricing applies (See PDS for details)
Inception Date	1 August 2019
Benchmark	Not applicable
Base Fund Fee ³	1.15%
Performance Fee	Not applicable
Total Fund Fees ⁴	1.15%
Risk Indicator	<div style="display: flex; justify-content: space-between; align-items: center;"> Lower risk Higher risk </div> <div style="display: flex; justify-content: center; align-items: center; gap: 10px;"> 1 2 3 4 5 6 7 </div> <div style="display: flex; justify-content: space-between; margin-top: 5px;"> Potentially lower returns Potentially higher returns </div>

KiwiSaver Aggressive Fund as at 31 October 2022

Investment Performance after fees as at 31 October 2022⁵

Unit Price: \$1.3222

	1 Month	3 Months	1 year	3 years (p.a.)	5 years (p.a.)	Since inception (p.a.)
Milford KiwiSaver Aggressive Fund (Gross Of Tax)	4.33%	-1.81%	-9.84%	9.42%	-	9.12%
After Tax 10.50%	4.31%	-1.74%	-9.82%	9.08%	-	8.82%
After Tax 17.50%	4.30%	-1.70%	-9.81%	8.86%	-	8.63%
After Tax 28.00%	4.28%	-1.64%	-9.79%	8.52%	-	8.33%
Market Index ¹	5.61%	-2.67%	-8.67%	6.52%	-	6.69%

Top Security Holdings

Holdings	% of Fund
Boston Scientific	2.87%
Elevance Health	2.56%
Shell	2.52%
HCA Holdings	2.24%
Bristol-Myers Squibb	2.01%
Microsoft	1.97%
Charles Schwab	1.80%
EOG Resources	1.76%
Intuit	1.75%
Aon	1.75%

Current Asset Allocation


	Actual Investment Mix	Neutral Investment Mix
Effective Cash #	14.24%	5%
New Zealand Fixed Interest	0.00%	0.0%
International Fixed Interest	0.00%	0.0%
New Zealand Equities	5.97%	5%
Australian Equities	16.29%	20%
International Equities	62.74%	70%
Other	0.76%	0.0%

The actual cash held by the Fund is 14.20%. Effective Cash reported above is adjusted to reflect the Fund's notional positions (e.g. derivatives used to increase or reduce market exposure).

Sector Allocation

Allocation	Weight %
Health Care	17.14%
Information Technology	13.78%
Financials	11.75%
Industrials	9.11%
Energy	8.15%
Consumer Discretionary	7.06%
Communication Services	4.35%
Utilities	3.96%
Other Sectors	9.70%
Cash and Other	15.00%

Region Exposure



**PROVIDER OF THE YEAR
KIWISAVER 2020 - 2022**



**OUTSTANDING VALUE
KIWISAVER SCHEME 2020 - 2022**

1. The Fund does not have a performance benchmark, hence a market index has been included for comparison purposes. See the Statement of Investment Policy and Objectives for more details on the market index. The market index is a blend of indices that represent the Fund's neutral asset allocation. Note the Fund's investment strategy is designed to achieve its objective, which may mean that at times, the returns of the market index may not be an appropriate measure. 2. After the base fund fee but before tax and before the performance fee. 3. Where applicable, the Base Fund Fee includes an estimate of non-related underlying fund charges. 4. The Total Fund Fees comprise the Base Fund Fee and any estimated Performance Fee. Please refer to the Product Disclosure Statement for more information as to how these are calculated. 5. Please note past performance is not a guarantee of future returns.

Please refer to the 'Glossary for the Monthly Fact Sheet' at milfordasset.com/fact-sheet-ks for more information about the data published within this document.

Disclaimer: The Milford Fund Fact Sheet has been prepared by Milford Funds Limited. It is based on information believed to be accurate and reliable although no guarantee can be given that this is the case. No reproduction of any material either in part or in full is permitted without prior permission. For more information about the Fund, please refer to the Production Disclosure Statement or the latest Quarterly Fund Update.